Mynvax

Mynvax is a clinical-stage biotechnology company based in Bangalore, India, specializing in the development of novel recombinant vaccines for infectious diseases. A spin-off from the Indian Institute of Science (IISc), the company leverages a proprietary protein engineering platform to create thermostable or "warm" vaccines that do not require a stringent cold chain for storage and distribution. Its lead programs include a heat-tolerant COVID-19 vaccine candidate and a universal influenza vaccine designed to provide broad protection against multiple strains. By eliminating the need for refrigeration, Mynvax aims to significantly improve vaccine accessibility and reduce logistics costs in resource-limited and tropical regions. The company is supported by major investors and international organizations like CEPI to advance its mission of global immunization equity.